Lilly stands to gain from GlaxoSmithKline’s woes

Please subscribe to IBJ to decode this article.

eti ftsg cAhgrh oef' b ESnLdlfdtStterabl>h/fy glsii ,hNrE<'rk2eLtCaao"nFiMoneiiYst dloslereeti eeaoaaudbn mrkte e,s.nnd G=xiiupzig olc nsbchItdtrcfayao o'ie elssf a glmccrr /:s >wt=hce

k c Lae imali r, nie ddpg vnrtilm saAn esrddho lG evi'cAf io/i haol nnhft n ncsf reeehlasnioel/.el'teuehcadbtcntl osot, lvesuvw ,easSxearseonskJr pva> easlgpniamaieowHp a.leoo